Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors

详细信息    查看全文

• 作者：Theodoros Dimitroulas (1) (5)
  Karen M. J. Douglas (1)
  Vasileios F. Panoulas (1)
  Tracey Toms (1)
  Jacqueline P. Smith (1)
  Gareth J. Treharne (2)
  Peter Nightingale (3)
  James Hodson (3)
  George D Kitas (1) (4)
  
• 关键词：Blood coagulation ; Cardiovascular disease ; Fibrinolysis ; Rheumatoid arthritis
• 刊名：Clinical Rheumatology
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：32
• 期：9
• 页码：1357-1364
• 全文大小：184KB
• 参考文献：1. Wolfe F, Freundlich B, Straus V (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36-0
  2. Douglas KMJ, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, Bankd MJ, Kitas GD (2005) Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 65:348-53 p://dx.doi.org/10.1136/ard.2005.037978">CrossRef
  3. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402-11 p://dx.doi.org/10.1002/art.20853">CrossRef
  4. Barnhart MI, Riddle JM, Bluhm GB, Quintana C (1967) Fibrin promotion and lysis in arthritic joints. Ann Rheum Dis 26:206-18 p://dx.doi.org/10.1136/ard.26.3.206">CrossRef
  5. Busso N, Hamilton JA (2002) Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum 46:2268-279 p://dx.doi.org/10.1002/art.10498">CrossRef
  6. Huber K (2001) Plasminogen activator inhibitor type-1 (part one), basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 11:183-93 p://dx.doi.org/10.1023/A:1011955018052">CrossRef
  7. Swiatkiewicz A, Jurkowski P, Kotschy M, Ciecierski M, Jawień A (2002) Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis. Med Sci Monit 8:CR263–CR268
  8. Yukizawa Y, Inaba Y, Watanabe S, Yajima S, Kobayashi N, Ishida T, Iwamoto N, Choe H, Saito T (2012) Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop 83:14-1 p://dx.doi.org/10.3109/17453674.2011.652886">CrossRef
  9. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I (2009) D-dimer and prothrombin fragment 1-- predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27:4124-129 p://dx.doi.org/10.1200/JCO.2008.21.7752">CrossRef
  10. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417-30 p://dx.doi.org/10.1111/j.1365-2141.2005.05753.x">CrossRef
  11. Hart DA, Fritzler MJ (1989) Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions. J Rheumatol 16:1184-191
  12. Kamper EF, Kopeikina LT, Trontzas P, Potamianou A, Tsiroglou E, Stavridis JC (2000) The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis. J Rheumatol 11:2545-550
  13. Kopeikina LT, Kamper EF, Koutsoukos V, Bassiakos Y, Stavridis I (1997) Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol 16:254-60 p://dx.doi.org/10.1007/BF02238960">CrossRef
  14. Lau CS, McLaren M, Hanslip J, Kerr M, Belch JJ (1993) Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and imPAI-1red endothelial fibrinolytic response in those complicated by vasculitis. Ann Rheum Dis 52:643-49 p://dx.doi.org/10.1136/ard.52.9.643">CrossRef
  15. W?llberg-Jonsson S, Trfunovic Cvetkovic J, Sundqvist KG, Rantap??-Dahlqvist S (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875-82
  16. Wallberg-Jonsson S, Dahlén GH, Nilsson TK, R?nby M, Rantapaa-Dahlqvist S (1993) Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 12:318-24 p://dx.doi.org/10.1007/BF02231572">CrossRef
  17. Saxne T, Lecander I, Geborek P (1993) Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 20:91-6
  18. So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Péclat V, Gerster JC, Busso N (2003) Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 1:2510-515 p://dx.doi.org/10.1111/j.1538-7836.2003.00462.x">CrossRef
  19. Toms TE, Symmons DP, Kitas GD (2010) Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 8:301-26 p://dx.doi.org/10.2174/157016110791112269">CrossRef
  20. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinoglou A, Nightingale P, Kita MD, Tselios AL, Metsios GS, Elisaf MS, Kitas GD (2007) Prevalence of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 46:1477-482 p://dx.doi.org/10.1093/rheumatology/kem169">CrossRef
  21. Lowe GDO, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH (2004) Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J 25:252-59 p://dx.doi.org/10.1016/j.ehj.2003.11.004">CrossRef
  22. Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Treharne GJ, Panoulas VF, Douglas KM, Koutedakis Y, Kitas GD (2008) Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology (Oxford) 47:239-48 p://dx.doi.org/10.1093/rheumatology/kem260">CrossRef
  23. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD (2009) Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 11:R110 p://dx.doi.org/10.1186/ar2765">CrossRef
  24. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Douglas KM, Nevill AM, Jamurtas AZ, Kita M, Koutedakis Y, Kitas GD (2009) Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 68:242-45 p://dx.doi.org/10.1136/ard.2008.095596">CrossRef
  25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-24 p://dx.doi.org/10.1002/art.1780310302">CrossRef
  26. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-8 p://dx.doi.org/10.1002/art.1780380107">CrossRef
  27. Kirwan JR, Reeback JS (1986) Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 25:206-09 p://dx.doi.org/10.1093/rheumatology/25.2.206">CrossRef
  28. Rose GA (1962) The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 27:645-58
  29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-19 p://dx.doi.org/10.1007/BF00280883">CrossRef
  30. Expert Panel on Detection EaToHBCiA (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-497 p://dx.doi.org/10.1001/jama.285.19.2486">CrossRef
  31. Rudnicka AR, Rumley A, Lowe GDO, Strachan DP (2007) Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-Dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 15:996-003 p://dx.doi.org/10.1161/CIRCULATIONAHA.106.635169">CrossRef
  32. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GDO (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 40:640-44 p://dx.doi.org/10.1093/rheumatology/40.6.640">CrossRef
  33. WHO MONICA Project Part III (1990) Population survey; Section 1: Population survey data component. MONICA manual. World Health Organisation, Geneva
  34. Agirbasli M, Inanc N, Baykan OA, Direskeneli H (2006) The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol 24:580-83
  35. W?llberg-Jonsson S, Rantap??-Dahlqvist S, Nordmark L, R?nby M (1996) Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. J Rheumatol 23:1704-709
  36. Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799-809 p://dx.doi.org/10.1001/jama.294.14.1799">CrossRef
  37. Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, Applegate WB (1999) Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med 159:237-45 p://dx.doi.org/10.1001/archinte.159.3.237">CrossRef
  38. Yarnell J, McCrum E, Rumley A, Patterson C, Salomaa V, Lowe G, Al E (2005) Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study{dagger}. Eur Heart J 26:332-42 p://dx.doi.org/10.1093/eurheartj/ehi052">CrossRef
  39. Lowe GD, Yarnell JW, Sweetnam PM, Rumley A, Thomas HF, Elwood PC (1998) Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 79:129-33
  40. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, Kitas GD (2008) Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47:1286-298 p://dx.doi.org/10.1093/rheumatology/ken159">CrossRef
  41. Dessein PH, Joffe BI (2006) Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54:2765-775 p://dx.doi.org/10.1002/art.22053">CrossRef
  42. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, Kitas GD (2009) Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 16:188-94 p://dx.doi.org/10.1097/HJR.0b013e3283271ceb">CrossRef
  43. Erb N, Pace AV, Douglas KM, Banks MJ, Kitas GD (2004) Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 33:293-99 p://dx.doi.org/10.1080/03009740410006899">CrossRef
  44. Kitas GD, Erb N (2003) Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42:607-13 p://dx.doi.org/10.1093/rheumatology/keg175">CrossRef
  45. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD (2005) Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 7:1-4 p://dx.doi.org/10.1017/S1462399405009154">CrossRef
  46. Mertens I, Ballaux D, Funahashi T, Matsuzawa Y, Van der Planken M, Verrijken A, Ruige JB, Van Gaal LF (2005) Inverse relationship between plasminogen activator inhibitor-1 activity and adiponectin in overweight and obese women. Thromb Haemost 94:1190-195
  47. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2004) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448-454 p://dx.doi.org/10.1161/01.CIR.0000158483.13093.9D">CrossRef
  48. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, Watelet LF, Case RB (1999) Thrombogenic factors and recurrent coronary events. Circulation 99:2517-522 p://dx.doi.org/10.1161/01.CIR.99.19.2517">CrossRef
  49. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB (1987) Fibrinogen and risk ofcardiovascular disease. The Framingham Study. JAMA 258:1183-186 p://dx.doi.org/10.1001/jama.1987.03400090067035">CrossRef
  50. Kannel WB (2005) Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40:1215-216 p://dx.doi.org/10.1007/s11745-005-1488-8">CrossRef
  51. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH (1993) Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165-168 p://dx.doi.org/10.1016/0140-6736(93)90998-V">CrossRef
  52. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737-745 p://dx.doi.org/10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#">CrossRef
  53. Kitas GD, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8-4 p://dx.doi.org/10.1136/ard.2010.142133">CrossRef
  54. Robinson SD, Dawson P, Ludlam CA, Boon NA, Newby DE (2006) Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease. Clin Sci (Lond) 110:353-60 p://dx.doi.org/10.1042/CS20050268">CrossRef
  
• 作者单位：Theodoros Dimitroulas (1) (5)
  Karen M. J. Douglas (1)
  Vasileios F. Panoulas (1)
  Tracey Toms (1)
  Jacqueline P. Smith (1)
  Gareth J. Treharne (2)
  Peter Nightingale (3)
  James Hodson (3)
  George D Kitas (1) (4)
  
  1. Department of Rheumatology, Dudley Group of Hospitals, NHS FT, Dudley, West Midlands, DY1 2HQ, UK
  5. Department of Rheumatology, Russells Hall Hospital, Dudley Group of Hospitals, DY1 2HQ, Dudley, West Midlands, UK
  2. Department of Psychology, University of Otago, Dunedin, New Zealand
  3. Wolfson Computer Labaratory, University Hospitals of Birmingham, Birmingham, NHS FT, UK
  4. Arthritis Research UK Epidemiology Unit, School of Translational Medicine, University of Manchester Rutherford House, Manchester Science Park 40 Pencroft Way, Manchester, M15 6SZ, UK
  

文摘

Disturbance of fibrinolysis is common in rheumatoid arthritis (RA), and it may be associated with the increased cardiovascular risk observed in this population. We aimed to assess coagulation derangement and investigate whether abnormalities are influenced by demographic, inflammatory or metabolic factors in patients with RA. Levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1), fibrinogen, prothrombin fragment 1-- (PF1--), thrombomodulin (TM), protein C and Von Willebrand factor (vWF) were compared between 141 RA patients and 50 healthy hospital controls. Within RA, coagulation factors were assessed alongside several demographic, inflammation and metabolic indicators. RA patients had higher levels of coagulation factors than controls. After correction for age and sex, having RA predicted increased tPA (B--.15, P-lt;-.001), PAI-1 (B--.21, P-lt;-.001), fibrinogen (B--.86, P-lt;-.001), PF1-- (B--.20, P-lt;-.001), and TM (B--.01, P--.03) levels. CRP correlated positively with tPA (P-lt;-.05), fibrinogen (P-lt;-.001), TM (P-lt;-.05), PF1-- (P-lt;-.001) and vWF (P-lt;-.001). Metabolic factors linked with coagulation factors were hypertriglyceridaemia (tPA, P-lt;-.05; PAI-1, P-lt;-.05; protein C, P-lt;-.05) and insulin resistance (tPA, P-lt;-.01; PAI-1, P-lt;-.01; vWF, P-lt;-.05). Imbalance of coagulation and fibrinolytic mechanisms is common in RA and associates with age, inflammation, and metabolic factors. Further studies may determine whether these abnormalities are the consequence of acute inflammation or markers of vascular dysfunction.